Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | FDPS | P14324 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | RECQL | P46063 | 2/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | PTPRA | P18433 | 1/20 | 0.41 |
| ▸ | PTPRB | P23467 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28281268 | 0.82 | ALDH1A1 (0.43) | SMN1; SMN2HIF1AFDPSALDH1A1RECQL | |
| SCHEMBL8694819 | 0.79 | SMN1; SMN2 (0.48) | SMN1; SMN2HIF1AFDPSALDH1A1RECQL | |
| SCHEMBL934104 | 0.78 | SMN1; SMN2 (0.52) | SMN1; SMN2HIF1AFDPSALDH1A1RECQL | |
| SCHEMBL2678813 | 0.78 | SMN1; SMN2 (0.52) | SMN1; SMN2HIF1AFDPSALDH1A1RECQL | |
| SCHEMBL4595472 | 0.77 | SMN1; SMN2 (0.60) | SMN1; SMN2HIF1AFDPSALDH1A1RECQL | |
| SCHEMBL3272549 | 0.77 | PPARG (0.59) | SMN1; SMN2HIF1AALDH1A1RECQLPPARG | |
| SCHEMBL3272547 | 0.77 | PPARG (0.59) | SMN1; SMN2HIF1AALDH1A1RECQLPPARG | |
| SCHEMBL9716385 | 0.76 | MAPT (0.49) | SMN1; SMN2FDPSCES1 | |
| SCHEMBL9620362 | 0.76 | MAPT (0.49) | SMN1; SMN2FDPSCES1 | |
| SCHEMBL9620173 | 0.76 | MAPT (0.49) | SMN1; SMN2FDPSCES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230255989-A1 | GLYCAN COMPOSITIONS AND USES THEREOF | DSM NUTRITIONAL PRODUCTS LLC (US) | 2023-08-17 | — | — | US | disclosed |
| US-11229660-B2 | Glycan therapeutics and method of treating conditions associated with TMAO | KALEIDO BIOSCIENCES, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-20210137956-A1 | GLYCAN COMPOSITIONS AND USES THEREOF | HERCULES CAPITAL, INC. | 2021-05-13 | — | — | US | disclosed |
| US-20210113596-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | KALEIDO BIOSCIENCES, INC. (US) | 2021-04-22 | — | — | US | disclosed |
| US-10881676-B2 | Glycan therapeutics and related methods thereof | KALEIDO BIOSCIENCES, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-10702542-B2 | Glycan therapeutics and related methods thereof | KALEIDO BIOSCIENCES, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20200093851-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | HERCULES CAPITAL, INC. | 2020-03-26 | — | — | US | disclosed |
| US-20200093845-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | HERCULES CAPITAL, INC. | 2020-03-26 | — | — | US | disclosed |
| US-20190391092-A1 | METABOLIC PROFILING WITH MAGNETIC RESONANCE MASS SPECTROMETRY (MRMS) | Oregon Institute of Science and Medicine | 2019-12-26 | — | — | US | disclosed |
| US-10314853-B2 | Glycan therapeutics and related methods thereof | KALEIDO BIOSCIENCES, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-20160213702-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | KALEIDO BIOSCIENCES, INC. (US) | 2016-07-28 | — | — | US | disclosed |
| US-8926743-B2 | Metal pigment, method for producing the same, and water base metallic resin composition including the same | TOYO ALUMINIUM KABUSHIKI KAISHA (JP) | 2015-01-06 | — | — | US | disclosed |
| US-20120129998-A1 | METAL PIGMENT, METHOD FOR PRODUCING THE SAME, AND WATER BASE METALLIC RESIN COMPOSITION INCLUDING THE SAME | TOYO ALUMINIUM KABUSHIKI KAISHA (JP) | 2012-05-24 | — | — | US | disclosed |
| EP-2452985-A1 | METALLIC PIGMENT, METHOD FOR PRODUCING SAME, AND AQUEOUS METALLIC RESIN COMPOSITION CONTAINING SAME | Toyo Aluminium Kabushiki Kaisha (JP) | 2012-05-16 | — | — | EP | disclosed |
| US-20120021061-A1 | MEDICAL AND NUTRITIONAL FORMULATIONS | COMVITA NEW ZEALAND LIMITED (NZ) | 2012-01-26 | — | — | US | disclosed |
| US-20110287059-A1 | HONEY ANALYSIS | COMVITA NEW ZEALAND LIMITED (NZ) | 2011-11-24 | — | — | US | disclosed |
| EP-2367444-A1 | MEDICAL AND NUTRITIONAL FORMULATIONS | Comvita New Zealand Limited (NZ) | 2011-09-28 | — | — | EP | disclosed |
| EP-2368111-A1 | HONEY ANALYSIS | Comvita New Zealand Limited (NZ) | 2011-09-28 | — | — | EP | disclosed |
| WO-2010082845-A1 | HONEY ANALYSIS | COMVITA NEW ZEALAND LIMITED (NZ) | 2010-07-22 | — | — | WO | disclosed |
| WO-2010082846-A1 | MEDICAL AND NUTRITIONAL FORMULATIONS | COMVITA NEW ZEALAND LIMITED (NZ) | 2010-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120021061-A1 | MEDICAL AND NUTRITIONAL FORMULATIONS | FABP6, NNT, IAPP | SMN1; SMN2 1079/4885HIF1A 1181/4885FDPS 681/4885 |
| US-20110287059-A1 | HONEY ANALYSIS | GLO1, GLMN, AGER | SMN1; SMN2 3941/4885HIF1A 1571/4885FDPS 2715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.